Hiding in Plain Sight: The Widespread Infections Quietly Circulating Among Americans Who Feel Perfectly Fine

The familiar image of an infected person — feverish, exhausted, visibly unwell — is, in many respects, a medical fiction. For a substantial number of common pathogens, the human body serves as a willing and entirely unsuspecting host, sustaining active infection without triggering the alarm signals most people associate with being sick. No fever. No fatigue. No reason to stay home or seek care. Just a person going about their daily life while quietly seeding a pathogen into their community.

This is not a marginal phenomenon. Across a range of infectious diseases, asymptomatic and presymptomatic presentations account for a strikingly large proportion of total cases — and, critically, a disproportionate share of ongoing transmission. The epidemiological data, taken together, suggest that the infections Americans are aware of may represent only a fraction of the infections Americans actually have.

The Scope of the Problem

The COVID-19 pandemic forced a broad reckoning with the concept of asymptomatic transmission, but the scientific community had long recognized the pattern in other diseases. Chlamydia, the most commonly reported sexually transmitted infection in the United States, is estimated by the Centers for Disease Control and Prevention to go undiagnosed in the majority of those infected — largely because roughly 70 to 95 percent of women and up to half of men with active chlamydial infections experience no symptoms whatsoever. The CDC estimates that of the approximately 4 million new chlamydia infections occurring annually in the US, a significant portion are never detected, diagnosed, or treated.

Hepatitis C presents a similarly sobering picture. The virus can replicate in the liver for decades without producing symptoms, during which time it causes progressive hepatic damage and remains transmissible through blood-to-blood contact. The CDC has estimated that as many as 40 percent of people living with chronic hepatitis C in the United States are unaware of their status. Given that the virus affects an estimated 2.4 million Americans, that translates to hundreds of thousands of individuals who have no idea they are infected.

Herpes simplex virus type 2 (HSV-2) follows a comparable pattern. Studies consistently show that the majority of individuals with HSV-2 have never received a clinical diagnosis, largely because many never develop recognizable outbreaks. Viral shedding — the process by which the virus becomes transmissible — occurs even in the absence of visible lesions, meaning transmission can occur between partners who both believe themselves uninfected.

Why Screening Protocols Fall Short

If these infections are this common, the obvious question is why standard clinical encounters so rarely surface them. The answer is partly structural and partly cultural.

In primary care settings, routine screening for asymptomatic infections is constrained by time, cost, and guideline specificity. The US Preventive Services Task Force recommends chlamydia and gonorrhea screening for sexually active women under 25 and for older women at elevated risk — but those recommendations do not extend universally to men who have sex with women, a population that may harbor and transmit infection without ever being screened. Hepatitis C screening guidelines have broadened in recent years to include all adults aged 18 to 79, a significant improvement, but implementation in clinical practice remains inconsistent.

For many infections, there is simply no universal screening recommendation at all. Cytomegalovirus (CMV), for instance, infects an estimated 50 to 80 percent of American adults by age 40. In immunocompetent individuals, it causes no symptoms and is rarely tested for. Yet in pregnant women, primary CMV infection carries meaningful risk of congenital transmission — making CMV the leading infectious cause of birth defects in the United States. Despite this, routine prenatal CMV screening is not standard practice in the US, in contrast to protocols in several other high-income countries.

Silent Reservoirs and Community Spread

The concept of a disease reservoir — a population or environment in which a pathogen persistently circulates without necessarily causing overt disease — is central to understanding how infections sustain themselves at the community level. When that reservoir is human and ambulatory, the epidemiological implications are substantial.

Consider the dynamics of influenza during a typical transmission season. Modeling studies have estimated that anywhere from 20 to 30 percent of influenza infections in a given season may be asymptomatic, with infected individuals still capable of shedding virus. In a densely populated urban environment, a single asymptomatic commuter on public transit can generate dozens of exposures in a single morning. Multiply that across tens of thousands of undetected infections in a metropolitan area, and the arithmetic of silent spread becomes difficult to ignore.

Tuberculosis, though less immediately transmissible, illustrates a different dimension of the same problem. Latent TB infection — in which Mycobacterium tuberculosis is present in the body but not actively replicating — affects an estimated 13 million people in the United States, according to CDC estimates. Most will never develop active disease. But in individuals whose immune function declines due to aging, immunosuppressive therapy, or HIV co-infection, latent infection can reactivate into contagious pulmonary TB. The latent reservoir, invisible and unmonitored in many cases, remains a persistent public health liability.

The Detection Gap and Its Consequences

The distance between infection prevalence and diagnosis rates — what might be called the detection gap — has real consequences that extend well beyond individual health outcomes. Undiagnosed infections drive transmission chains that standard contact tracing cannot map, because there is no diagnosed index case from which to work backward. They allow treatable conditions to progress to serious complications: untreated chlamydia advancing to pelvic inflammatory disease, undetected hepatitis C advancing to cirrhosis, latent TB reactivating in a vulnerable host.

They also distort the data that public health authorities use to allocate resources and design interventions. When surveillance systems capture only symptomatic cases, they systematically undercount the true burden of disease — and the resulting epidemiological picture is incomplete at best, misleading at worst.

Toward a More Proactive Screening Culture

Addressing this problem requires a shift in how both clinicians and patients think about infectious disease. The assumption that feeling well is equivalent to being uninfected is, for a meaningful range of pathogens, epidemiologically unsound. Routine, risk-stratified screening — expanded in scope and more consistently implemented — offers the most direct path toward closing the detection gap.

That means normalizing conversations about sexual health screening regardless of symptom status, ensuring that hepatitis C testing is genuinely universal in primary care rather than aspirationally so, and investing in the public health infrastructure needed to reach populations least likely to engage with routine clinical care. It also means communicating clearly to the public that an absence of symptoms is not a reliable indicator of an absence of infection.

The infections circulating silently through American communities are not invisible because they are rare. In many cases, they are invisible because the systems designed to find them are not looking hard enough — or in the right places.